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Purpose: Various retinal proteins are newly exposed to immune system in a process of tissue destructive endogenous
uveitis. Some of such proteins could be autoantigens that extend the ocular inflammation in human endogenous uveitis.
In this study, we aimed to investigate the possibility of such spreading of autoantigens in endogenous uveoretinitis using
a proteomic approach.
Methods: Experimental autoimmune uveoretinitis (EAU) was induced in mice by inoculation with a peptide consisting
of amino acids 1–20 (GPTHLFQPSLVLDMAKVLLP) of interphotoreceptor retinoid binding protein (IRBP). Six weeks
after immunization, the presence of autoantibodies against the retinal proteins in mice with EAU were examined by two-
dimensional electrophoresis followed by western blotting (2D-WB). Retinal proteins targeted by the autoantibodies were
identified by mass spectrometry (MS) and their autoantigenicity in patients with endogenous uveitis, such as Behcet’s
disease (BD, n=36), Vogt-Koyanagi-Harada disease (VKH, n=16), and sarcoidosis (n=17) were examined by enzyme-
linked immunosorbent assay.
Results: Six new candidate autoantigens, which were detected in mice with EAU using 2D-WD were identified by MS as
β-actin, esterase D (EsteD), tubulin β-2, brain-type creatine kinase (BB-CK), voltage-dependent anion-selective channel
protein, and aspartate aminotransferase. Among the patients with endogenous uveitis, 25% of BD and 25% of VKH patients
were positive for anti-EsteD antibody, and 25% of VKH and 38.4% of sarcoidosis patients were positive for anti-BB-CK
antibody.
Conclusions:  Autoantibodies  to  EsteD  and  BB-CK  produced  in  EAU-induced  mice  were  also  detected  in  some
endogenous uveitis patients, suggesting that these proteins might be autoantigens spreading in a process of endogenous
uveoretinitis.
Endogenous  uveitis,  represented  by  Behcet’s  disease
(BD),  Vogt-Koyanagi-Harada  disease  (VKH),  and
sarcoidosis, is a sight-threatening ocular inflammation. While
the pathogenesis of endogenous uveitis is considered to be
related to autoimmunity [1-4], the underlying mechanism is
not fully understood. Previous reports have suggested the
involvement of several autoantigens in the pathogenesis of
endogenous  uveitis.  For  example,  autoimmunity  against
ocular-specific  antigens  [5-7],  heat-shock  protein  (HSP)
family [4,8], and ubiquitously expressed proteins [9,10] were
reported in BD, and autoimmunity against the melanocyte-
associated antigens [11-13] were reported in VKH. However,
some of these antigens show autoantigenicity in more than one
endogenous uveitis, suggesting the existence of autoantigens
that are not disease-specific. For example, autoimmunity to
HSP70 was reported in both BD and sarcoidosis [3,4], and
autoimmunity to S-antigen was reported in BD, sarcoidosis,
Correspondence  to:  Masaru  Takeuchi,  Department  of
Ophthalmology, Tokyo Medical University, 6-7-1 Nishishinjyuku
Shinjyuku-ku,  Tokyo,  Japan;  Phone:  +81-3-5339-3759;  FAX:
+81-3-3346-9170; email: takeuchi@tokyo-med.ac.jp
and VKH [3]. Although VKH is regarded as a melanocyte
specific autoimmune disease, there are reports of autoantigens
besides melanocyte specific proteins [3-14]. Therefore, it is
considerable that a number of autoantigens are involved in
patients with endogenous uveitis.
To explain the phenomena that common antigens are
targeted in several endogenous uveitis, we hypothesized that
uveitis-mediated  destruction  of  ocular  tissue  leads  to  the
exposure of ocular antigens to the immune system, which in
turn induces the production of antibodies against some of
these antigens secondary to the ocular damage. Even though
such secondary induced antigens may not participate in the
disease-specific  pathogenesis  in  endogenous  uveitis,  they
may  modulate  different  endogenous  uveitis  in  the  same
manner.  Thus,  identifying  the  profile  of  secondary
autoantigens will be of primary importance to understand the
pathogenesis of endogenous uveitis. For that purpose, we
applied  a  proteomic  approach  using  two-dimensional  gel
electrophoresis  and  western  blotting  (2D-WB).  Both
procedures have been shown by us and others to be useful in
Molecular Vision 2008; 14:1094-1104 <http://www.molvis.org/molvis/v14/a130>
Received 7 June 2007 | Accepted 11 May 2008 | Published 12 June 2008
© 2008 Molecular Vision
1094identifying circulating autoantibodies in autoimmune diseases
[15,16].
In this study, we first used the interphotoreceptor retinoid
protein (IRBP)-induced murine model of autoimmune uveitis
(experimental autoimmune uveoretinitis, EAU) for detecting
autoantigens exposed as a result of uveitis-mediated tissue
destruction. We screened circulating autoantibodies in mice
with  EAU  against  the  retinal  proteins  using  2D-WB  and
subsequently  identified  the  proteins  targeted  by  the
autoantibodies  using  mass  spectrometry  (MS).  We  then
evaluated  the  autoantigenicity  of  these  identified  retinal
proteins in patients with endogenous uveitis (BD, VKH, and
sarcoidosis).
METHODS
Patients: Serum samples were obtained from 36 BD patients
with uveitis (31 men, 5 women; average age 36.9±10.5 years),
16  patients  with  VKH  (12  men,  4  women;  average  age
39.2±12.6 years), and 17 patients with sarcoidosis (4 men, 13
women;  average  age  59.6±17.6  years).  All  patients  were
followed up by the outpatient clinic of the Department of
Ophthalmology  in  Tokyo  Medical  University  Hospital,
Tokyo, Japan. Participants were considered to have BD if their
symptoms  fulfilled  the  diagnostic  criteria  of  the  Bechet’s
Disease Research Committee of Japan [17]. At the time of
sample collection, BD patients were determined to be in the
active phase of the disease if they presented with one of the
following  indicators:  iridocyclitis  with  hypopyon,  dense
vitreous  opacity,  obscure  fundi  observation,  and  retinal
exudates with hemorrhages. All VKH patients showed typical
exudative  retinal  detachment  confirmed  by  fluorescein
angiography.  Sera  were  collected  in  these  patients  before
aggressive systemic corticosteroid therapy was begun. Three
of  the  VKH  patients  were  examined  when  they  were
experiencing a recurrent phase of ocular inflammation. Ocular
sarcoidosis was diagnosed based on the criteria established by
the Japanese Committee for Diffuse Lung Disease for the
systemic sarcoidosis [18,19]. In total, 64 healthy volunteers
(35 men, 29 women), who were age- and sex-matched for each
uveitis group, were recruited as healthy controls (HC). The
investigation was conducted in accordance to the tenets of the
Declaration of Helsinki.
Animals and reagents: C57BL/6 female mice, aged 6 to 9
weeks, were obtained from Sankyo Laboratory Service Corp
(Tokyo, Japan). Animals were handled in accordance with the
Association for the Vision and Ophthalmology statement for
the  use  of  Animals  in  Ophthalmic  and  Vision  research.
Horseradish peroxidase (HRP)-conjugated rabbit antimouse
IgG  and  goat  antihuman  IgG  were  obtained  from  Zymed
Laboratories (San Francisco, CA). Human IRBP peptide 1–
20 (hIRBP-p) was synthesized by conventional solid-phase
techniques on a peptide synthesizer (Takara Bio Inc., Shiga,
Japan).  Complete  Freund’s  adjuvant  (CFA)  and
Mycobacterium  tuberculosis  H37Ra  were  purchased  from
Difco (Detroit, MI), Bordetella pertussis (PTX) was from
Sigma-Aldrich Corp (St. Louis, MO), purified human β-actin
(bAct) was from Cytoskeleton (Denver, CO), recombinant
human esterase D (EsteD) was from GenWay Biotech (San
Diego, CA), brain-type creatine phosphokinase (BB-CK) was
from Biogenesis (Poole, England), and pETBlue-2 and Turner
(DE3) pLacIcompetent cell were from Novagen (Darmstadt,
Germany).
Induction  and  scoring  of  experimental  autoimmune
uveoretinitis: Induction of EAU in C57BL/6 mice and scoring
of  ocular  inflammation  were  performed  as  previously
described [19]. Briefly, mice were immunized subcutaneously
in the occipital region with 200 μg hIRBP-p in 200 μl emulsion
in CFA that had been supplemented with H37Ra to 5 mg/ml.
Next, 1 μg PTX was given intraperitoneally as an additional
adjuvant. On day 18 after immunization, ocular inflammation
was clinically evaluated on a scale of 0 to 4 according to the
previous report [20]. Briefly, minimal vasculitis with few very
small lesions were scored as 0.5; mild vasculitis with 5 or less
small focal chorioretinal lesions as 1; multiple (more than 5)
chorioretinal lesions or severe vasculitis as 2; pattern of linear
choreioretinal  lesions,  subretinal  neovascularization,  and
haemorrhages as 3; and large retinal detachment and retinal
atrophy as 4. The sera of the mice scoring over 1.5 were
collected  six  weeks  after  immunization  and  used  as  the
primary antibody in 2D-WB. Control mice were immunized
with only CFA and PTX and then processed in the same way
as the EAU mice.
Protein extract preparation: Mice were killed by cervical
vertebra dislocation, and then retina from ten normal C57BL/
6 female mice were separated immediately after enucleation
and whole-tissue lysates were prepared by the freeze–thaw
method using a lysis buffer that contained 7 M urea, 2 M
thiourea,  and  4%  CHAPS  [21].  The  supernatant  of  each
sample  was  collected,  mixed  together,  and  then  stored  at
−80 °C until used.
Two-dimensional  western  blotting:  Two-dimensional
electrophoresis was performed as described previously [21,
TABLE 1. CANDIDATE RETINAL AUTOANTIGENS DETECTED IN EXPERIMENTAL AUTOIMMUNE
UVEORETINITIS BY 2D-WB
Positive rate
Spot number Control EAU p value*
103 0/10 10/10 5.4×10-6
30 2/10 6/10 0.084
71 2/10 6/10 0.084
131 0/10 4/10 0.043
29 0/10 3/10 0.105
34 0/10 3/10 0.105
59 0/10 3/10 0.105
We detected seven candidate autoantigens by comparing the
positive  rate  of  each  spot  between  the  experimental
autoimmune uveoretinitis (EAU) and control by referring to
the p value of the positive rate. The asterisk indicates Fisher’s
exact probability test.
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1095Figure 1. Detection of autoantigens in experimental autoimmune uveoretinitis (EAU). A: Shown is a two-dimensional gel image of murine
retinal proteins stained with SYPRO Ruby. Approximately 2,000 spots were observed. Among the SYPRO Ruby stained protein spots, the
2D-WB positive spots either in control or EAU were randomly numbered. The numbers and the positions of the seven candidate autoantigens
in EAU on a SYPRO Ruby stained gel are shown in panel A. The spot numbers of the candidate autoantigens are common between panel
B, Table 1, and Table 2. B: Extracted murine retinal proteins were separated by two-dimensional electrophoresis, transferred onto nitrocellulose
membranes. Western blotting was performed using sera from EAU or control mice. Representative membranes reacted with sera from complete
Freund's adjuvant-treated control mice are shown in subpanel C, and those reacted with sera from EAU mice are shown in subpanel E. Each
set of C and E subpanels shows the corresponding area. Arrowheads indicate the position of each candidate autoantigen on the EAU
membranes. membranes.
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109622]. Briefly, 100 μg extracted protein was applied on 11 cm
linear Immobiline Drystrips, pH 3–10 (GE Healthcare Bio-
Science  Corp.,  Piscataway,  NJ)  and  rehydrated  at  room
temperature  for  10  h.  Isoelectric  focusing  (IEF)  was
performed  using  Ettan  IPGphorII  (GE  Healthcare  Bio-
Science Corp.) for 12 h. After IEF, the strips were equilibrated
for 30 min in a denaturation buffer that contained 6 M urea,
2% sodium dodecyl sulfate (SDS), 50 mM Tris-HCl, 30%
glycerol, and 100 mg/10 ml dithiothreitol (DTT). Strips were
then embedded onto 12.5% sodium dodecyl sulfate (SDS)-
polyacrylamide  gels,  and  gels  were  run  for  2.5  h.  After
electrophoresis,  the  separated  proteins  on  the  gels  were
transferred  onto  nitrocellulose  membranes.  For  2D-WB,
membranes were blocked in phosphate-buffered saline with
0.1%  Tween20  (PBST)  containing  0.5%  bovine  serum
albumin (BSA) for 30 min and washed three times with PBST
(10 min each time). Membranes were incubated for 1 h in
1:500 times diluted murine serum samples in 0.5% BSA-
PBST. Next, membranes were washed with PBST before they
were  incubated  for  1  h  with  1:2000  diluted  HRP  rabbit
antimouse  IgG.  Bound  antibodies  were  visualized  using
diaminobenzidine (DAB; Dojindo Laboratories, Kumamoto,
Japan).
Protein identification: Protein spots, which corresponded to
the EAU-positive spots on the 2D-WB, were recovered from
a  2D  gel  stained  with  SYPRO  Ruby  (Molecular  Probes,
Eugene, OR) and digested in gel with trypsin. The digested
peptides  were  extracted  from  the  gel  pieces  using
trifluroacetic acid and acetonitrile. After centrifugation, the
supernatant was recovered. After three more cycles of this
extraction,  the  supernatant  was  filtered  and  concentrated
down to 10 μl in an evaporator [23,24]. Masses of the digested
peptides  were  determined  using  a  matrix-assisted  laser
desorption/ionization-time  of  flight  mass  spectrometer
(MALDI-TOF MS; Ultraflex, Bruker Daltonics, Germany).
A list of the determined peptide masses were subjected to mass
fingerprinting  by  using  the  MASCOT  software  program
version 2.1.0 (Matrix, Science, London UK), in which the
National Center for Biotechnology Information (Bethesda,
MD) protein data base was searched [25]. Only those proteins
with  a  Mowse  score  above  statistical  significant  identity
(p<0.05) were accepted as identified ones.
Recombinant protein: Based on the nucleotide sequence of
the human tubulin-β (Tub-b) cDNA, the entire protein-coding
region  of  the  Tub-b  cDNA  from  the  murine  retina  was
amplified using specific pairs of oligonucleotide primers. The
amplified cDNA fragment was subcloned into the plasmid
expression  vector  pETBlue-2,  and  then  the  protein  was
expressed in Escherichia coli Turner (DE3) pLacIcompetent
cells. Thereby, recombinant Tub-b with a tag of six histidines
in its COOH-terminal was produced. The purification of Tub-
b  was  performed  as  follows  by  brief  modification  of  the
previous report [26]. The bacteria was harvested from a 500
ml culture by centrifugation, lysed in 10 ml of lysozyme
solution (0.2 mg/ml lysozyme, 1% NP-40 in PBS), and then
sonicated to fragment the bacterial DNA. 0.1 mg DNase and
10 mmol MgCl2 were added to the sonicated sample. 25 min
after, 20 ml of denaturation buffer was added to make final
concentration of 8 M urea, 12 mM 2-mercaptoethanol, and 10
mM imidazol. After centrifugation, the sample was filtered,
and then the protein was purified using a histidine-Ni+ affinity
column (His Trap HP; GE Healthcare Bioscience Corp.) The
sample was applied to the column and eluted with an elution
buffer (10 mM-500 mM imidazol, 8 M Urea in PBS, pH 7.6).
One-dimensional western blotting: One-dimensional (1D)-
WB  was  performed  as  follows.  Each  protein  (4  μg)  was
separated by 12.5% SDS–PAGE in a buffer that contained
DTT, and then transferred onto nitrocellulose membranes.
The serum samples were diluted to 1:200 in 1% BSA-PBST
and  used  for  incubation  with  the  membranes  for  1  h.
Incubation of the membranes with the secondary antibody and
treatment  with  DAB  were  performed  as  described  in  the
previous section for 2D-WB.
Enzyme-linked  immunosorbent  assay  (ELISA):  Ninty-six-
well microtiter plates (Thermo Labsystems, Franklin, MA)
TABLE 2. IDENTIFICATION OF CANDIDATE RETINAL ANTIGENS IN EXPERIMENTAL AUTOIMMUNE UVEORETINITIS
Spot
number
Protein name
NCBI accession
number
Calculated MW
(kDa)/pI
MOWSE
scorea
Peptides matched
(coverage; %)
MS/MS sequenceb
103
retinol binding protein 3,
interstitial
gi|21729751 134/4.98 208 4 (5%)                  IGQSNFFLTVPVSR
30 beta-actin (bAct) gi|49868 39.4/5.78 83 1 (4%)                  SYELPDGQVITIGNER
71 esterase D (EsteD) gi|55777188 31.8/6.70 52 3 (14%)                 SYGQQAASEHGLVVIAPDTSPR
131 tubulin beta-2 (Tub-b) gi|13542680 50.2/4.79 144 3 (8%)                  FPGQLNADLR
29
creatin kinase, brain (BB-
CK)
gi|10946574 42.9/5.4 209 3 (11%)                 VLTPELYAELR
34
voltage-dependent anion-
selective channel protein
gi|10720404 32.5/8.55 39 1 (6%)                  WNTDNTLGTEITVEDQLAR
59 aspartate aminotransferase gi|871422 46.4/6.68 142 4 (10%)                 VGGVQSLGGTGALR
aProteins with MOWSE score over statistical significant identity (p<0.05) were accepted as identified.  bFor the proteins in which
several peptides were matched, the peptide identified with the highest MOWSE score is shown.
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1097Figure 2. The presence of antibodies to bAct, EsteD, and BB-CK in EAU mice was confirmed by 1D-WB and ELISA. A-C: Protein (2 μg)
was  subjected  to  12.5%  SDS–PAGE,  transferred  onto  nitrocellulose  membranes,  then  incubated  with  1:200  sera  from  experimental
autoimmune uveoretinitis (EAU) or control mice and 1:2000 horse radish peroxide (HRP) antimouse IgG as described in Methods. EAU
serum samples were 8/10 positive in bAct (A), 6/10 positive in EsteD (B), and 4/10 positive in brain-type creatine kinase (BB-CK; C). D-F:
Antibody titer of the sera from the EAU or control mice was determined by ELISA. The antibody titer was calculated as binding units according
to the formula shown in Methods. EAU serum samples were 4/10 positive in bAct (D), 7/10 positive in EsteD (E), and 4/10 positive in BB-
CK (F). Lane 1 is ponseau S staining, lane 2-4 are membranes incubated with EAU sera, and lane 5-7 are membranes incubated with control
sera. In the figure, M represents molecular weight marker.
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1098were coated with 5 ug/ml of EsteD, bAct, or BB-CK at 4 °C
for 16h in a carbonate buffer which contained 50 mM sodium
carbonate. The plates were washed three times with PBST
then incubated in 1% BSA-PBST at room temperature for 1
h. The plates were again washed three times, and 50 μl of
1:200 diluted serum samples were added to each well. The
plates were incubated for 2 h, and then washed five times with
PBST.  Following  incubation  with  1:2000  HRP-goat  anti-
human IgG for 1 h, the plates were washed eight times with
PBST. Color development was achieved by adding 100 μl of
0.04% o-phenylenediamine as a substrate. The reactivity of
the serum sample to each protein was expressed using the
arbitrary binding units, calculated according to the following
formula:  sample  (binding  units)=(OD  sample/[mean  OD
control sera + 2SD of control sera] × 100), where OD is the
optical density. According to the formula, 100 binding units
were used as the cutoff point.
IgG1 and IgG2a subclasses of anti-EsteD and anti-BB-
CK antibodies were determined using the mouse IgG1 and
IgG2a quantitation kits (Bethyl laboratories, Montgomery,
TX). Briefly, EsteD or BB-CK was coated onto the microtiter
plates as described in the previous section, and serum samples
diluted to 1:100 were used for the detection of IgG1 and
undiluted samples were used for the detection of IgG2a.
Statistical analysis: Fisher’s exact probability test was used
to compare differences in the prevalence of autoantibodies
between  the  HC  and  each  disease  group.  Fisher’s  exact
probability  test  or  Student’s  t-test  was  used  to  compare
differences in the clinical parameters or clinical symptoms
between the antibody-positive and -negative patient groups.
RESULTS
Detection of retinal autoantigens involved in experimental
autoimmune  uveoretinitis:  EAU  was  induced  in  C57BL/6
mice by immunization with hIRBP-p. Clinical severity was
evaluated  18  days  after  immunization.  As  a  result,
approximately 70% of hIRBP-p immunized mice developed
ocular inflammation, with the clinical score of more than 1.5.
We  used  sera  from  ten  EAU  and  ten  control  mice  to
comprehensively detect retinal autoantigens by 2D-WB, and
we obtained a total of 151 protein spots that reacted positively
with any of the tested sera. Though the control and EAU sera
Figure 3. IgG subclass of anti-EsteD and anti- brain-type creatine kinase antibodies in experimental autoimmune uveoretinitis mice were
determined by ELISA. Concentrations of anti-EsteD and anti- brain-type creatine kinase (BB-CK) IgG1 antibodies in all tested serum samples
of experimental autoimmune uveoretinitis were much higher than those of anti-EsteD and anti-BB-CK IgG2a antibodies. All control serum
samples collected from mice immunized without hIRBP-p were negative for both IgG1 and IgG2a.
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1099showed similar positive pattern on 2D-WB, we detected seven
candidate autoantigens (Figure 1A and Table 1) by comparing
the positive rate of each spot between the EAU and control by
referring to the respective p value. For this purpose, the p value
for a protein spot reacting positively to three EAU sera and no
control sera was determined to be 0.105, and we chose all the
spots as candidate autoantigens whose p values were 0.105 or
less. Spot positions of five major candidate autoantigens are
shown in Figure 1B.
The MALDI-TOF MS and MS/MS analysis were used to
identify the seven candidate autoantigens and the results of
MS/MS  analysis  are  summarized  in  Table  2.  One  spot
(number 103), which reacted with 100% of the EAU sera but
none of the control sera, was identified as the commonly
known retinal binding protein 3 (rbp3). Rbp3 contains the 20
amino acid sequence of the hIRBP-p used for the induction of
EAU. Thus, the positive reaction to this protein spot in all the
EAU sera was due to the initial immunoresponse against the
hIRBP-p used for immunization. It is therefore possible that
the remaining six proteins were candidate retinal autoantigens
induced as a result of EAU-mediated retinal destruction.
Confirmation of immunoreactivity of candidate autoantigens
in  experimental  autoimmune  uveoretinitis:  Among  the
candidate autoantigens, we chose the four antigens, bAct,
EsteD, Tub-b, and BB-CK, for further analysis. We selected
bAct, EsteD, and Tub-b because their p values were low
(Table 1), and BB-CK because it was a relatively retina- and
brain-specific protein. To confirm the aforedescribed results
of  the  2D-WB,  we  evaluated  autoantibody  titers  against
recombinant bAct, EsteD, Tub-b, and BB-CK in the EAU
mice by using 1D-WB and ELISA. 1D-WB analysis showed
that  8/10,  6/10,  and  4/10  EAU  mice  were  positive  for
autoantibodies against the antigens of bAct, EsteD, and BB-
CK, respectively (Figure 2A,B,C); in contrast, none of the
control  mice  reacted  positively  with  any  of  these  three
antigens. Similarly, ELISA analysis showed that 4/10, 7/10,
and 4/10 EAU mice were positive for autoantibodies against
the antigens of bAct, EsteD, and BB-CK, respectively (Figure
2D,E,F). The results of the 2D-WB, 1D-WB, and ELISA
corresponded closely to one another. Similar ELISA results
were obtained using another set of control and EAU sera
collected six weeks after immunization (data not shown). In
addition, when we compared the antibody level against bAct,
EsteD, and BB-CK using the murine sera collected three, six,
and ten weeks after the immunization, we found that the sera
collected six weeks after the immunization had the highest
levels of antibodies against these three antigens (data not
shown). As Tub-b did not react with the EAU sera in either
1D-WB or ELISA (data not shown), it was not used for any
further experiments.
IgG subclass of anti-EsteD and anti-BB-CK antibodies: IgGs
are  subclassified  depending  on  the  types  of  Th  immune
responses. Th1-mediated immune response promotes IgG2a
production, while Th2-mediated immune response promotes
IgG1 production. Thus, we next determined the subclass of
the anti-EsteD and the anti-BB-CK antibodies. Interestingly,
most of the anti-EsteD and anti-BB-CK antibodies in all the
tested EAU serum samples were IgG1, and the amount of
IgG2a type of the anti-EsteD and anti-BB-CK antibodies were
much lower than their respective IgG1 antibodies (Figure 3).
All control serum samples collected from the mice immunized
without hIRBP-p were negative for both IgG1 and IgG2a (data
not shown).
Autoantigenicity in human uveitis: As shown in the previous
section, bAct, EsteD, and BB-CK were confirmed as retinal
autoantigens  in  the  murine  model  of  autoimmune  uveitis.
Because the amino acid sequence of these three autoantigens
are highly conserved in human and mouse (approximately 91–
100%),  we  next  examined  whether  autoantibodies  against
these antigens could be detected in human endogenous uveitis.
We examined the immunoreactivity against bAct, EsteD,
and BB-CK by ELISA in 36 BD, 16 VKH, and 17 sarcoidosis
patients with uveitis and age- and sex-matched HC. A profile
of these patients is given in Table 3. Patients with the medical
history of all four symptoms associated with BD (oral aphthae,
skin lesion, genital ulcer, and uveitis) were 36.1%. For the
VKH group, patients with active ocular inflammation before
the starting of aggressive corticosteroid therapy were used,
because high dose corticosteroid therapy would dramatically
suppress immune response and antibody titers would also be
strongly suppressed. As shown in Figure 4, EsteD reacted with
the  sera  from  25%  of  BD,  25%  of  VKH,  and  17.6%  of
TABLE 3. PROFILE OF PATIENTS WHOSE SERA WERE USED FOR ANTIBODIES DETECTION BY ELISA
Parameter BD (n=36) VKH (n=16) Sarcoidosis (n=17)
Age (year) 36.9±10.5 39.2±12.6 59.6±17.6
Sex (Male:Female) 31:5 8:8 4:13
Active ocular inflammation 52.8% 100% 76.4%
Duration from the onset 4.8±4.1 (year) 8.8±10.5 (day) 6.2±5.3 (yr)
LogVA -1.18±1.14 -0.43±0.48 -0.36±0.52
Administration of systemic corticosteroid 32.1% 12.5% 5.9%
In the table “duration from the onset” refers to the interval from the onset of the disease to the day when blood was collected.
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1100sarcoidosis patients, and the percentages were significantly
higher in BD (p=0.016) and VKH (p=0.015) groups than in
the control group. BB-CK reacted with sera from 5.6% of BD,
25% of VKH, and 38.4% of sarcoidosis patients. Percentages
were significantly higher in VKH (p=0.015) and sarcoidosis
(p=0.020) groups than in the control group. One sample each
in BD and sarcoidosis and two samples in VKH were positive
for both EsteD and BB-CK. However, bAct did not react
positively with any of the uveitis sera with any statistical
significance (data not shown).
Next, we compared the clinical parameters of patients
between the anti-EsteD antibody and anti-BB-CK antibody
positive- and negative-patient groups in each uveitis group.
As shown in Table 4, every anti-EsteD antibody positive VKH
patient in this group was female. Results from this group were
statistically significant compared to the anti-EsteD antibody
negative VKH group (p=0.034). In the case of the BD or
sarcoidosis  patients,  there  were  no  statistically  relevant
correlations  between  the  examined  parameters  (age,  sex,
disease  duration,  visual  acuity,  activity  of  ocular
inflammation, serum IgG levels, systemic medications at the
time  of  sample  collection,  presence  of  HLA-B51,  or
involvement of systemic diseases) and the presence of either
anti-EsteD or anti-BB-CK antibody (results not shown).
DISCUSSION
We have identified six candidates of retinal autoantigens in
EAU,  out  of  which  two,  EsteD  and  BB-CK,  showed
autoantigenicity in both human endogenous uveitis and EAU.
EsteD (EC 3.1.1.1) is a 282 amino acid cytoplasmic protein
(31.4 kDa) that is ubiquitously expressed and functions as a
nonspecific esterase. Our study showed that the murine retina
expressed EsteD, and a previous work reported the presence
of  EsteD  in  human  retinal  pigment  epithelium  [27].
Considering  that  EsteD  is  expressed  abundantly  in  other
tissues such as liver, kidney, and intestine [28], there is a
possibility that the anti-EsteD antibody would be found in
other autoimmune diseases. However, our present study is the
first to show EsteD is a target of autoimmunity in uveitis. In
this study, three out of four anti-EsteD antibody-positive VKH
patients were examined when they were experiencing their
first episode of ocular inflammation, and one patient was
examined when experiencing a recurrent phase. Our results
suggest  that  even  though  VKH  is  a  melanocyte-specific
autoimmune disease, autoimmunity to antigens other than
melanocyte-specific  proteins  are  induced  from  the  early
period of uveitis, and these autoantibodies may modulate the
disease.  Several  reports  about  the  melanocyte-unrelated
antigens in VKH support this idea [3,14]. In the VKH group,
all of the anti-EsteD positive patients were female, and the
Figure 4. Autoantibodies against the retinal autoantigens detected in experimental autoimmune uveoretinitis were tested using sera from human
endogenous uveitis patients. The antibody titer was calculated as binding units according to the formula given in Methods. Statistically
significant difference of positive rate between each patient group and healthy control (HC) was detected in Behcet’s disease (BD; p=0.016)
and Vogt-Koyanagi-Harada disease (VKH; p=0.015) for anti-EsteD antibody, and in VKH (p=0.015) and sarcoidosis (p=0.036) for anti- brain-
type creatine kinase (BB-CK).
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1101result was statistically significant. However, a larger number
of patients are needed to determine that female VKH patients
are commonly positive for anti-EsteD antibody.
Another retinal autoantigen detected both in EAU and
human uveitis was BB-CK (EC 2.7.3.2). This is a 381 amino
acid  cytoplasmic  enzyme  (42.6  kDa)  that  is  abundantly
expressed in brain and retina, and its expression in retina has
been  mentioned  in  several  reports  [29,30].  Autoantibody
production against BB-CK was also reported in patients with
paraneoplastic  sensory-dominant  neuropathy  [31].
Interestingly,  autoantigens  common  to  both  the
paraneoplastic  syndrome  and  endogenous  uveitis  were
reported previously. For example, it was shown that the anti-
α-enolase antibody was present both in BD [9] and cancer-
associated retinopathy [32-35], a paraneoplastic syndrome
that affects visual function. Considering BB-CK is relatively
abundant  in  the  retina,  the  anti-BB-CK  antibody  may
modulate vision-related functions in anti-BB-CK antibody-
positive patients, although statistical differences in the clinical
parameters were not observed in the present study.
BD,  sarcoidosis,  and  VKH  exhibit  clinically
distinguishable ocular manifestations, and their etiologies and
pathogenesis  are  also  different.  We  did  not  observe  any
statistical correlation between the patients positive for these
antibodies  and  the  disease  parameters.  The  only
distinguishing  feature  in  this  study  was  all  anti-EsteD
antibody  positive  patients  were  female.  We  suggest  that
production of anti-EsteD antibody or anti-BB-CK antibody
might be unrelated to the type of uveitis—that is, regardless
of the classification of uveitis, some of the patients would be
TABLE 4. STATISTICAL ANALYSIS OF CLINICAL PARAMETERS BETWEEN ANTI-ESTED POSITIVE
AND NEGATIVE PATIENTS OF VOGT-KOYANAGI-HARADA DISEASE
Parameter P (n=4) N (n=12) p value
Age (year) 35.8±12.7 42.1±10.3 0.41a
Sex (M:F) 0:4 8:4 0.04b
HLA-DR4 75% (n=4) 77.8% (n=9) 0.91b
LogVA -0.49±0.61 -0.42±0.21 0.84a
IgG (mg/ml) 11.6±2.1 10.1±3.7 0.46a
Four  anti-EsteD  antibody  positive  Vogt-Koyanagi-Harada
(VKH)  patients and 12 anti-EsteD antibody negative VKH
patients were statistically compared their age, sex, Log visual
acuity (VA), and serum concentration of total IgG. For the
analysis of HLA-DR4, four anti-EsteD antibody positive and
9 anti-EsteD antibody negative VKH patients were analysed.
Age, LogVA, and serum IgG concentration were compared
by Student’s t test, and sex and the presence of HLA-DR4
were compared by Fisher’s exact probability test. Anti-EsteD
antibody positive VKH patients were all female and it was
statistically  significant  compared  to  anti-EsteD  antibody
negative VKH patients. There was no statistical difference in
other  examined  factors. aStudent’s  t  test; bFisher’s  exact
probability test.
positive  for  these  antibodies.  It  would  be  worthwhile  to
examine a greater number of patients to further understand the
roles of these autoantibodies in endogenous uveitis.
Some proteins are secondary exposed to immune system
in a process of autoimmune disease. Some of such proteins
could be autoantigenic and become one of the factors that
extend inflammation. Several mechanisms, such as epitope
spreading, molecular mimicry, and bystander activation, have
been  reported  in  various  animal  models  of  autoimmune
disease and in some human autoimmune diseases [36,37]. In
the present study, the anti-EsteD and anti-BB-CK antibodies
were mainly of the IgG1 subclass, production of which is
promoted by Th2-type cytokine. However, EAU is considered
to be a Th1 disease. Therefore, it is possible that anti-EsteD
and anti-BB-CK antibodies were produced as a result of Th2
immune responses promoted in the process of downregulating
EAU. However, we can not define immune responses against
EsteD or BB-CK in the development of endogenous uveitis
with the results described in this study. We plan to study the
immunogenicity including antigenicity of these proteins. In
this regard, although it is a preliminary experiment, it is worth
mentioning here that we have recently immunized C57BL/6
mice and Lewis rats with these two autoantigens; however,
we did not observe uveitis in these animals until day 21 after
immunization. This result tends to support the idea that any
immune response against these two autoantigens is, indeed, a
secondary reaction to tissue damage caused by the primary
uveitogenic process.
Among the EAU-associated retinal autoantigens found in
this study, all but BB-CK are ubiquitously and abundantly
expressed  proteins.  These  results  suggest  that  in  an
underactivated immune system, even ubiquitously expressed
antigens  would  become  a  target  of  organ-specific
autoimmunity.  Considering  that  none  of  the  previously
reported ocular-specific autoantigens in endogenous uveits
(such as S-antigen, rhodopsin [38], and recoverin [39]) were
detected as candidate retinal autoantigens in the present study,
ubiquitously  expressed  proteins  appear  to  be  more
immunogenic among antigens exposed to immune system
secondarily under tissue-destructive severe uveitis.
In  conclusion,  our  study  demonstrated  that
autoantibodies were produced against several proteins in EAU
induced by immunization with an IRBP-derived peptide. Of
these, autoantibodies specific for EsteD and BB-CK were also
detected in human endogenous uveitis. Therefore, we suggest
that EsteD and BB-CK might be autoantigens secondarily
generated as a result of uveitis-induced retinal destruction.
Our  approach  of  using  an  animal  model  of  autoimmune
disease to comprehensively detect autoantibodies was useful
in  identifying  new  autoantigens.  We  believe  that  similar
approaches will also facilitate the detection of autoantigens in
other autoimmune diseases.
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